Arcus Biosciences Inc (RCUS)
Debt-to-equity ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 485,000 | 462,000 | 657,000 | 842,000 | 502,000 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $—K ÷ $485,000K
= 0.00
Based on the provided data, the debt-to-equity ratio for Arcus Biosciences Inc has consistently been 0.00 from December 31, 2020, to December 31, 2024. A debt-to-equity ratio of 0.00 indicates that the company has no debt in relation to its equity during this period. This suggests that Arcus Biosciences Inc has been primarily relying on equity financing rather than debt financing to fund its operations and growth. This low debt-to-equity ratio can be seen as a positive indicator of financial stability and lower financial risk for the company, as it implies lower leverage and less financial strain from debt obligations. However, it's important to consider that a very low debt-to-equity ratio might also mean missed opportunities for leveraging debt to potentially enhance returns for shareholders.
Peer comparison
Dec 31, 2024